Introducdon
The National Childhood Vaccine Injury Act of 1986 mandated that the US government conduct a scientific review of the possible adverse consequences of all childhood vaccines.' The Vaccine Safety Committee of the Institute of Medicine published its conclusions about adverse reactions of pertussis and rubella vaccines in 19912 and about the other childhood vaccines in 1993. 3 In the 1993 report, the Institute of Medicine concluded that "the evidence favored acceptance of a causal relation between tetanus toxoid (and therefore tetanus-toxoid-containing vaccines (TTCV)) and Guillain-Barre syndrome (GBS) ."3 This conclusion was based on biological plausibility and a striking case report, from 1978, of a 42-year-old man who received tetanus toxoid on three occasions during a 13-year period and developed a self-limited episode of Guillain-Barre syndrome after each vaccination. This man also experienced multiple subsequent episodes of Guillain-Barre syndrome following acute viral illnesses. Several other case reports of Guillain-Barre syndrome following tetanus-toxoid-containing vaccines among adult patients exist, as does a single report of Guillain-Barre syndrome following diptheria, tetanus, and pertussis (DTP) vaccination in a child with exacerbation following tetanus-diptheria (Td) vaccination as an adolescent (National Vac- We examined data from a previous study conducted by two of us (H.R., J.D.C.), which investigated the relationship between the administration of oral polio vaccine (OPV) and Guillain-Barre syndrome in children in Southern California'°( doses of tetanus-toxoid-containing vaccine were administered over the 7-month period in this study population (Table 1) .
During the CDC Guillain-Barre syndrome and influenza vaccine study, 213 cases of Guillain-Barre syndrome were observed in the study population, of which 12 occurred within 6 weeks of influenza vaccination. None of the 12 people with these cases had simultaneously received a tetanus-toxoid-containing vaccine, and all were excluded from the calculation of the Guillain-Barre syndrome background rate of 0.3 cases per million person-weeks (Table 1) .
On the basis of NHIS and Biologics Surveillance data, 1.3 to 2 cases, respectively, of Guillain-Barre syndrome could be expected to occur within 6 weeks of tetanus-toxoid vaccine by chance alone. In contrast, 1 case of Guillain-Barre syndrome was actually observed within 6 weeks of tetanus-toxoid vaccination in the GuillainBarre syndrome and influenza study.
Children
Ninety-three children fulfilled the diagnostic criteria for acute Guillain-Barre syndrome in this study population. Of these, only four had received vaccinations within the preceding 6 weeks. Two of these children, approximately 2.5 and 3 years old, had received DTP (simultaneously with other vaccines.
If we apply the estimated age-specific background rates of Guillain-Barre syndrome in the population to the estimated number of DTP vaccine doses delivered in this population, 1.4 cases of Guillain-Barre syndrome would be expected to occur within 6 weeks of DTP vaccination by chance alone in children less than 2 years of age (Table 2 ). In the 2-through 5-year-old age group, 1.07 cases of Guillain-Barre syndrome would be expected to occur within 6 weeks of DTP vaccination by chance.
Overall, 2.4 cases of Guillain-Barre syndrome would be expected for all children aged 5 years or younger. Only 2 cases of Guillain-Barre syndrome within 6 weeks of DTP vaccination were observed in the study.
Discussion
Acute inflammatory demyelinating polyneuritis, or Guillain-Barre syndrome, is characterized by the rapid onset of flaccid motor weakness with hyporeflexia and elevation of protein levels in the cerebrospinal fluid without pleocytosis. Whether this would be a prudent use of resources given the rarity of the potential association is debatable. Irrespective of this question, our analyses show that if an association between Guillain-Barre syndrome and tetanus-toxoid-containing vaccine exists, it is unlikely to be large enough to be of significant public health importance.
Guillain-Barre syndrome after swine influenza vaccination'6 was found to have an attributable risk of 1 in 100000 doses. At the other extreme, vaccine-associated paralytic polio on the order of 1 in 2.5 million doses'7 is enough to push for a change to the inactivated polio vaccine/oral polio vaccine schedule. These associated risks are of sufficient magnitude to cause public concern.
The Institute of Medicine's conclusion that tetanus-toxoid-containing vaccines can cause Guillain-Barr6 syndrome was based on limited data, primarily a single case report of an individual with apparently unusual susceptibility to Guillain-Barre syndrome. Using data from two large, active surveillance studies in which adult and child populations received an estimated 0.7 million to 1.2 million and 8.1 million doses, respectively, of tetanus-toxoid-containing vaccine, we have shown that the number of cases of Guillain-Barre syndrome observed after administration of such vaccines in both adults and children is less than the number expected by chance alone. We therefore conclude that on the basis of available data, no association of public health significance exists between tetanus-toxoid-containing vaccine and Guillam-Barre syndrome. D2
